Hem › Äggstockscancer › Ohio › Columbus
Kliniska studier för Äggstockscancer i Columbus, OH
39 studier för Äggstockscancer söker deltagare vid platser i och runt Columbus (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RekryterarFas 2/3
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekryterarFas 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- och 13 fler
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RekryterarFas 1/2
- Research Site, Columbus
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekryterarFas 2
- The Mark H Zangmeister Center /ID# 275106, Columbus
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekryterarFas 2
- Site 0243 - Mark H Zangmeister Cancer Center, Columbus
- Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi bort
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekryterarObservationsstudie
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekryterarFas 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
RekryterarFas 1/2
- The Ohio State University Wexner Medical Center, Columbus
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
RekryterarFas 2
- Research Site, Columbus
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekryterarFas 3
- The Mark H Zangmeister Center, Columbus
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10 mi bort
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekryterarFas 2
- Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard · 10 mi bort
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekryterarFas 3
- Ohio Health Research Institute, Columbus
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekryterarFas 2
- The Mark H Zangmeister Cancer Center Ohio, Columbus
- The Ohio State University Wexner Medical Center Division of Gynecologic Oncology, Hilliard · 10 mi bort
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekryterarFas 2
- The Ohio State University Comprehensive Cancer Center, Hilliard · 10 mi bort
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekryterarFas 1/2
- Ohio State University, Columbus
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RekryterarFas 3
- Zangmeister Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekryterarFas 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RekryterarFas 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekryterarFas 3
- OhioHealth Research Institute, Columbus
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekryterarFas 1
- The Ohio State University, Columbus
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RekryterarFas 1
- Ohio State University Wexner Medical Center, Columbus
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
RekryterarTidig fas 1
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- The Ohio State University, Columbus
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
RekryterarFas 3
- Site 0108, Columbus
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekryterar
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- och 8 fler
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekryterarFas 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- och 8 fler
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekryterarFas 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RekryterarFas 2/3
- Ohio State University Wexner Medical Center, Hilliard · 10 mi bort
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekryterarFas 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekryterarFas 2
- Ohio State University, Columbus
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
Lead-212 PSV359 Therapy for Patients With Solid Tumors
RekryterarFas 1/2
- Ohio State University, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RekryterarFas 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
RekryterarFas 1
- Ohio State University-James Cancer Hospital and Solove Research Institute, Columbus
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RekryterarFas 1/2
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekryterarFas 1/2
- Stefanie Spielman Comprehensive Breast Center, Columbus
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RekryterarFas 2
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RekryterarFas 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekryterarObservationsstudie
- Massive Bio SYNERGY-AI site, Columbus
Äggstockscancer-studier i andra städer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
- Pittsburgh, PA30 studier
Andra studier i Columbus
- Icke-småcellig lungcancer57 studier
- Bröstcancer40 studier
- Cancer (alla typer)38 studier
- Lungcancer37 studier
- Akut myeloid leukemi35 studier
- Kronisk lymfatisk leukemi28 studier
- Metastaserande cancer27 studier
- Endometriecancer25 studier
- Prostatacancer24 studier
- Multipelt myelom24 studier
- Kolorektal cancer24 studier
- Melanom21 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.